NEW ONCE-A-MONTH POSTMENOPAUSAL OSTEOPOROSIS DRUG AVAILABLE

Recently, the U.S. Food and Drug Administration (FDA) approved a new once-a-month dose of Actonel® (risedronate sodium) tablets making it the only oral once-a-month osteoporosis therapy approved to help prevent both spinal and non-spinal fractures in postmenopausal women. The new once-a-month dose of Actonel is available for patients seeking the fracture protection of Actonel in the convenience of one monthly pill. In addition to being approved to help protect the spine from fractures, Actonel is also approved to help prevent non-spinal fractures, measured as a group, namely the hip, wrist, collar bone, arm, pelvis, and leg.